share_log

交银国际:重申中国生物制药(01177.HK)“买入”评级 目标价4.8港元

JRJ Finance ·  Jul 11 22:09

交银国际发布研究报告称,重申中国生物制药(01177.HK)“买入”评级,上调2024-26年净利润预测2%-3%,以反映更强的业绩增速复苏能见度,目标价4.8港元。

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment